Steroid receptor content in human ovarian tumors: Survival of patients with ovarian carcinoma related to steroid receptor content

Endocrine Factors in Common Epithelial Ovarian Cancer*

“…In most studies, no correlation between receptor content and stage of disease could be demonstrated (96,102,104,109,113,114,117,118,122,124).…”

“…Some investigators found an association between positivity for ER and poor differentiation (98,108). Others found that well differentiated tumors more frequently contained ER (103,113) or both ER and PR (101,135). No correlation between the presence of AR and tumor histology was found (116,124).…”

“…Information on the prognostic importance of steroid receptors in ovarian cancer is less known. Early reports, suggesting a relationship between presence of PR and a better prognosis, were hampered by the fact that the number of cases were small and that only the patient status (dead or alive) or median survival time of receptor-positive and receptor-negative cases were evaluated (92,107,113,135).…”

“…Presence of ER and PR in combinations in epithelial ovarian cancer Investigator Janne et al, 1980 Quinn et al, 1982 Jones et al, 1983 Kauppila et al, 1983 Leibach et al, 1983 Pollow et al, 1983 Spona et al, 1983 Teufel et al, 1983 Willcocks et al, 1983 Wurz et al,Geyer et al, 1984Lantta, 1984Iversen et al, 1986Toppila et al, 1986 Kuhnel et al, 1987 Bizzi et al, 1988 Jakobsen et al, 1988 Masood, 1988 Friedlander et al, 1989 Harding et al, 1990 …”

Clinical implication of estrogen-related receptor (ERR) expression in ovarian cancers

“…On the other hand, megesterol acetate proved to be useful for the patients who failed to respond to other forms of therapy [3], and the place of hormonal therapy in the management of patients with epithelial ovarian cancer needs more thorough evaluation in well-designed randomized trials [4]. As the aspect of steroid receptor expression in ovarian cancers, no stable information about patient prognosis has been reported as following: Only approximately 40% of the malignant tumors contained measurable amounts of estrogen receptor (ER) and progesterone receptor (PR) [5], the contents of ER and PR, especially of ER alone were not related to clinical stage and prognostic information [6], and epithelial cells in ovarian cancer tissue showed significantly lower mean immunoreactivity of ER␤ and PR, but not ER␣, than in normal ovarian tissue [7]. Although estrogens are not ligands for estrogen-related receptor (ERR), one type of orphan receptor, ERR may interact with ER in competition to use the common cofactors for transcription [8][9][10][11][12][13].…”